ArticleCell2023
Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
25.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 166 citations in OpenAlex.
- Protein glycosylation profiling in lung adenocarcinoma and precursor lesions: analysis of FFPE tissue sections.Analytical and bioanalytical chemistry · 2026Article
- Pan-Cancer Quantification of Driver Alteration Transmission Across Molecular Layers Reveals Limited Propagation to Protein Abundance.International journal of cancer · 2026Article
- Article
- Sweetening the bonds: how O-GlcNAcylation modulates cell adhesion.Acta pharmacologica Sinica · 2026Review
- The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications.Cancer metastasis reviews · 2026Review
- HDAC1 maintains metabolic homeostasis in nucleus pulposus cells via post-translational modification interactions with YBX1.Experimental & molecular medicine · 2026Article
- Integrated transcriptome analysis and machine learning to construct a homeostatic model of acetylation for bladder cancer and validate the key geneTranslational andrology and urology · 2026Article
- AURKB-mediated phosphorylation of metabolic enzyme CD73 drives immune suppression and renal cell carcinoma progression.Cell death and differentiation · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- Crosstalk between lactylation and other post-translational modifications in health and diseases.Molecular biomedicine · 2026Review
- Bimodality in pan-cancer proteomics reveals new opportunities for biomarker discovery.Genome biology · 2026Article
- Article
- Hijacking the Host: Post-Translational Modifications as Molecular Switches in HIV Persistence and Immune Evasion.Journal of medical virology · 2026Review
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma.Molecular cancer therapeutics · 2026Article
- Unraveling the enigma: Post-translational modifications in psychiatric disorders and their regulatory mechanisms.Journal of translational internal medicine · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- The β-hydroxybutyrylation of Zyxin ameliorates pulmonary fibrosis by inhibiting lung fibroblast activation through the PI3K/AKT pathway.Respiratory research · 2026Article
- Integrative interpretable learning reveals shared patterns of epitranscriptomic regulation across multiple cancer types.BMC biology · 2026Article
- Signal Transduction and Transcription Activator 1 in Pan-Cancer: Prognostic and Immunological Value.Clinical and experimental medicine · 2026Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 11 institutions in 2 countries.
Yifat GeffenBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA 02115, USA.
Shankara AnandBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Yo AkiyamaBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Tomer M YaronWeill Cornell Medical College, Meyer Cancer Center, New York, NY 10021, USA.
Yizhe SongWashington University School of Medicine, St. Louis, MO 63110, USA.
Jared L JohnsonWeill Cornell Medical College, Meyer Cancer Center, New York, NY 10021, USA.
Akshay GovindanWashington University School of Medicine, St. Louis, MO 63110, USA.
Özgün BaburDepartment of Computer Science, University of Massachusetts Boston, Boston, MA 02125, USA.
Yize LiWashington University School of Medicine, St. Louis, MO 63110, USA.
Emily HuntsmanWeill Cornell Medical College, Meyer Cancer Center, New York, NY 10021, USA.
Liang-Bo WangWashington University School of Medicine, St. Louis, MO 63110, USA.
Chet BirgerBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
David I HeimanBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Qing ZhangBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Mendy MillerBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Yosef E MaruvkaBiotechnology and Food Engineering, Lokey Center for Life Science and Engineering, Technion, Israel Institute of Technology, Haifa, Israel.
Nicholas J HaradhvalaBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Anna CalinawanDepartment of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Saveliy BelkinBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Alexander KerelskyWeill Cornell Medical College, Meyer Cancer Center, New York, NY 10021, USA.
Karl R ClauserBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Karsten KrugBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Shankha SatpathyBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Samuel H PayneDepartment of Biology, Brigham Young University, Provo, UT 84602, USA.
D R ManiBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Michael A GilletteBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA 02115, USA.
Saravana M DhanasekaranDepartment of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
Mathangi ThiagarajanLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Mehdi MesriOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Rockville, MD 20850, USA.
Henry RodriguezOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Rockville, MD 20850, USA.
Ana I RoblesOffice of Cancer Clinical Proteomics Research, National Cancer Institute, Rockville, MD 20850, USA.
Steven A CarrBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA.
Alexander J LazarDepartments of Pathology & Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
François AguetBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA. Electronic address: faguet@illumina.com.
Lewis C CantleyWeill Cornell Medical College, Meyer Cancer Center, New York, NY 10021, USA. Electronic address: lewis_cantley@dfci.harvard.edu.
Li DingWashington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: lding@wustl.edu.
Gad GetzBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142, USA; Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: gadgetz@broadinstitute.org.
Clinical Proteomic Tumor Analysis Consortium
Broad Institute · USWashington University in St. Louis · USCornell University · USCancer Clinic · USLeidos (United States) · USUniversity of Massachusetts Boston · USBrigham Young University · USIcahn School of Medicine at Mount Sinai · USTechnion – Israel Institute of Technology · ILThe University of Texas MD Anderson Cancer Center · USUniversity of Michigan · US
Funding
WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI CARRASCO, RUBEN D · 2016 to 2025
$17.0MRole of Phosphoinositides and Protein Kinases in the control of Cancer MetabolismR35CA197588 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LEWIS C. CANTLEY · 2016 to 2026
$10.2MProteogenomic Studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefitU01CA214114 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BIRRER, MICHAEL, PAULOVICH, AMANDA G · 2017 to 2021
$8.4MMICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALSU01CA214125 · NCI · BAYLOR COLLEGE OF MEDICINE · PI ANURAG, MEENAKSHI, CARR, STEVEN A · 2017 to 2021
$7.0MProteogenomic Translational Research Center for Clinical ProteomicU01CA214116 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI DRUKER, BRIAN J, RODLAND, KARIN D · 2017 to 2021
$6.8MCenter for Advanced Multi-Omic Characterization of CancerU24CA271012 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI Tao Liu · 2022 to 2026
$6.6MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA210986 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, GILLETTE, MICHAEL A · 2016 to 2020
$6.4MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA270823 · NCI · BROAD INSTITUTE, INC. · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.3MThe Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic TargetsU24CA210985 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2016 to 2020
$5.3MPNNL Proteome Characterization CenterU24CA210955 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI LIU, TAO, SMITH, RICHARD D · 2016 to 2020
$5.3MProteogenomic Predictors of Recurrence in Non-small Cell Lung CancerU01CA271402 · NCI · WASHINGTON UNIVERSITY · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.0MNCI NIH HHS 75N91019D00024NCI NIH HHS 75N91020C00029NCI NIH HHS P01 CA206978NCI NIH HHS R33 CA263705NCI NIH HHS R35 CA197588NCI NIH HHS U01 CA214114NCI NIH HHS U01 CA214116NCI NIH HHS U01 CA214125NCI NIH HHS U01 CA271402NCI NIH HHS U24 CA210954NCI NIH HHS U24 CA210955NCI NIH HHS U24 CA210967NCI NIH HHS U24 CA210972NCI NIH HHS U24 CA210979NCI NIH HHS U24 CA210985NCI NIH HHS U24 CA210986NCI NIH HHS U24 CA210993NCI NIH HHS U24 CA270823NCI NIH HHS U24 CA271012NCI NIH HHS U24 CA271075
Abstract
Post-translational modifications (PTMs) play key roles in regulating cell signaling and physiology in both normal and cancer cells. Advances in mass spectrometry enable high-throughput, accurate, and sensitive measurement of PTM levels to better understand their role, prevalence, and crosstalk. Here, we analyze the largest collection of proteogenomics data from 1,110 patients with PTM profiles across 11 cancer types (10 from the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium [CPTAC]). Our study reveals pan-cancer patterns of changes in protein acetylation and phosphorylation involved in hallmark cancer processes. These patterns revealed subsets of tumors, from different cancer types, including those with dysregulated DNA repair driven by phosphorylation, altered metabolic regulation associated with immune response driven by acetylation, affected kinase specificity by crosstalk between acetylation and phosphorylation, and modified histone regulation. Overall, this resource highlights the rich biology governed by PTMs and exposes potential new therapeutic avenues.
Indexed as
NeoplasmsProtein Processing, Post-TranslationalProteomicsAcetylationHistonesHumansPhosphorylationHistonesCPTACDNA damage responsegenomicsmass spectrometrymetabolismpan-cancerpost-translational modificationsproteomicstranscriptomics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.